Arbitel Plus 40 mg+12.5 mg Tablet (Telmisartan + HCT) – ACI Limited

1. About Arbitel Plus 40+12.5 mg (Telmisartan 40 mg + HCT)

Arbitel Plus 40+12.5 mg Tablet contains Telmisartan 40 mg (ARB) and Hydrochlorothiazide 12.5 mg (thiazide diuretic), manufactured by ACI Limited, Bangladesh. This is the starting-dose formulation of the Arbitel Plus range — appropriate for patients initiating ARB + thiazide combination therapy, or those transitioning from telmisartan 40 mg monotherapy who need a diuretic component added for better BP control.

At telmisartan 40 mg, patients receive effective RAAS blockade with a lower risk of first-dose hypotension compared to the 80 mg dose — safer for elderly patients or those who are volume-sensitive. Hydrochlorothiazide 12.5 mg provides gentle, well-tolerated diuresis with minimal electrolyte disruption at this low dose. Together, the combination produces additive antihypertensive effect, helping patients achieve BP targets more reliably than on either drug alone.

2. Mechanism of Action

Telmisartan 40 mg (ARB): Selective AT1 receptor blockade → inhibits angiotensin II vasoconstriction and aldosterone release → vasodilation, reduced blood volume, lower BP. 24-hour coverage. K+-sparing via aldosterone suppression partially offsets HCT hypokalaemia.

Hydrochlorothiazide 12.5 mg (Thiazide Diuretic): Inhibits distal tubular Na+/Cl− co-transporter → increased sodium and water excretion → reduced blood volume and preload → BP reduction. Secondarily reduces peripheral resistance with long-term use. Activates RAAS compensatorily — which telmisartan blocks, preventing escape and enhancing net antihypertensive effect.

3. Indications

• Hypertension inadequately controlled on telmisartan 40 mg alone
• Initiation of ARB + diuretic dual therapy in hypertensive patients new to combination treatment
• Elderly/volume-sensitive hypertensive patients requiring combination but intolerant of higher telmisartan doses
• Simplification for patients already taking telmisartan 40 mg + HCT 12.5 mg as two separate tablets
• Mild-to-moderate hypertension requiring more than monotherapy

4. Dosage and Administration

Standard: One tablet once daily in the morning. Provides telmisartan 40 mg + HCT 12.5 mg per day.

Step-up: If BP remains above target after 4–8 weeks, step up to Arbitel Plus 80+12.5 mg (higher telmisartan dose).

Morning dosing preferred to prevent nocturia. Take with or without food. Consistent daily timing important.

5. Contraindications

• Hypersensitivity to telmisartan, HCT, or sulfonamides
• Pregnancy (all trimesters)
• Severe renal impairment (eGFR <30 ml/min)
• Anuria, severe hepatic impairment
• Refractory hypokalaemia, hyponatraemia, hypercalcaemia
• Aliskiren co-administration in diabetes or eGFR <60 ml/min

6. Warnings and Precautions

Electrolytes: Monitor Na+ and K+ at baseline and periodically. HCT hypokalaemia risk is partially offset by telmisartan, but monitoring is essential, especially in elderly, those with poor oral intake, or concurrent corticosteroid/laxative use.

Renal function: Monitor creatinine and eGFR. Both components affected by renal impairment. HCT ineffective in severe CKD (<eGFR 30).

Glucose: HCT may slightly impair glucose tolerance. At 12.5 mg, effect is minimal, but monitor in T2DM patients. Telmisartan’s PPAR-γ activity partially counteracts this.

Uric acid: HCT raises serum uric acid. Monitor in patients with gout or hyperuricaemia.

Hypotension: More pronounced in volume-depleted patients. Telmisartan 40 mg is better tolerated than 80 mg in this regard — one advantage of the 40+12.5 formulation.

7. Side Effects

Common: Dizziness, headache, fatigue (telmisartan); polyuria/nocturia early in treatment (HCT), mild muscle cramps (K+ effect), back pain.

Uncommon: Hypokalaemia, mild hyponatraemia, elevated uric acid, impaired glucose tolerance, elevated creatinine.

Rare: Angioedema, photosensitivity (HCT), hepatic dysfunction, acute pancreatitis (HCT).

Advantage vs ACE inhibitors: No dry cough from telmisartan component.

8. Drug Interactions

• NSAIDs: Reduce efficacy of both components; increase renal impairment risk
• Lithium: Both components raise lithium levels — monitor closely
• Digoxin: Telmisartan raises digoxin Cmax; HCT hypokalaemia potentiates digoxin toxicity — monitor K+ and digoxin levels
• Antidiabetics: HCT may reduce glycaemic efficacy; adjust if needed
• K+-sparing diuretics: Complex K+ interaction — monitor electrolytes

9. Arbitel Plus 40+12.5 vs 80+12.5: Which to Choose?

Both Arbitel Plus formulations contain HCT 12.5 mg — the difference is telmisartan dose. Arbitel Plus 40+12.5 mg is preferred for: initiation of combination therapy, elderly patients, those with hepatic impairment (max 40 mg telmisartan), or patients sensitive to hypotension. Arbitel Plus 80+12.5 mg is preferred for: patients needing maximum RAAS blockade, those requiring ONTARGET-dose telmisartan for cardiovascular risk reduction, or those stepping up from the 40 mg formulation after adequate tolerance. Most patients are started on 40+12.5 mg and, if BP is not at target, stepped up to 80+12.5 mg.

10. Pharmacokinetics

Telmisartan 40 mg: Bioavailability ~42%. Biliary elimination. t½ 24h. No renal adjustment. HCT 12.5 mg: Bioavailability 65–75%. Renal elimination unchanged. t½ 6–15h. Onset 1–2h; peak effect 3–6h; duration 6–12h. Once-daily sufficient for antihypertensive maintenance, though diuretic peak is shorter than antihypertensive effect.

11. ACI Limited Arbitel Range — Complete Step-Up Strategy

ACI’s Arbitel range enables a complete step-up treatment strategy: Arbitel 20/40/80 mg (telmisartan monotherapy) → Arbitel AM 5+40/5+80 mg (+ amlodipine CCB) or Arbitel Plus 40+12.5/80+12.5 mg (+ HCT diuretic) → Triple therapy (ARB + CCB + diuretic) combining products from both ranges. This covers every stage of the hypertension treatment algorithm from initiation to resistant hypertension within a single manufacturer’s portfolio.

12. ACI Limited Arbitel Plus Range

Arbitel Plus 40+12.5 mg (initiation/elderly) and Arbitel Plus 80+12.5 mg (target dose) — both once-daily FDC tablets for ARB + thiazide combination therapy from ACI Limited Bangladesh.

13. Storage

• Below 30°C, cool, dry, protected from light and moisture
• Take in the morning. Original blister. Keep from children.
• Do not use after expiry.

Frequently Asked Questions (FAQ)

Q1: What is Arbitel Plus 40+12.5 mg used for?

Arbitel Plus 40+12.5 mg is a combination of Telmisartan 40 mg (ARB) and Hydrochlorothiazide 12.5 mg (thiazide diuretic) for hypertension when a single drug is insufficient for blood pressure control. It is the starting dose of the Arbitel Plus range — preferred for initiating combination ARB+diuretic therapy, for elderly patients, or for those with mild-moderate hypertension needing dual therapy. The two drugs work synergistically: diuretic reduces blood volume, ARB blocks the compensatory RAAS activation that would otherwise limit the diuretic’s effect.

Q2: How is Arbitel Plus 40+12.5 mg different from Arbitel Plus 80+12.5 mg?

The HCT dose is identical (12.5 mg). The difference is telmisartan: 40 mg vs 80 mg. The 40+12.5 mg formulation is the starting dose — provides moderate RAAS blockade with lower hypotension risk, suitable for initiation, elderly patients, and those with hepatic impairment (max telmisartan 40 mg). The 80+12.5 mg formulation is the step-up target dose — maximum RAAS blockade with cardiovascular evidence (ONTARGET 80 mg), stronger BP reduction, maximum renoprotection. Most patients start on 40+12.5 mg and step up to 80+12.5 mg if BP target not achieved in 4–8 weeks.

Q3: Will the HCT in Arbitel Plus cause too much urination?

Initial polyuria (increased urination) is expected when starting hydrochlorothiazide — especially in the first 1–2 weeks. At the low 12.5 mg dose in Arbitel Plus, this is mild and typically settles within 2–4 weeks as the kidneys adapt. Taking Arbitel Plus in the morning ensures any diuretic effect occurs during the day, not at night. Most patients find the mild diuresis well-tolerated and preferable to uncontrolled hypertension. If urination remains disruptive after 2 weeks, discuss with your physician — alternative antihypertensive combinations (e.g., Arbitel AM — ARB + CCB) may be considered.

Q4: Does Arbitel Plus interact with my diabetes medications?

Hydrochlorothiazide at higher doses can raise blood glucose and reduce the efficacy of oral antidiabetics. At the low 12.5 mg dose in Arbitel Plus, this effect is generally minimal. Telmisartan’s PPAR-γ partial agonism may modestly improve insulin sensitivity, partially offsetting any glucose-raising effect of HCT. Monitor blood glucose more frequently when initiating Arbitel Plus if you have T2DM. Notify your diabetologist so they can adjust your antidiabetic medication if needed. Importantly, Arbitel Plus should NOT be used in diabetic patients with severe CKD (eGFR <30 ml/min) — use Arbitel 80 mg or Arbitel AM instead.